Study In ASH Late-Breaking Abstracts Session: Next-Generation Targeted Therapy Zanubrutinib Found Superior To Ibrutinib For CLL And SLL
December 14, 2022
December 14, 2022
WASHINGTON, Dec. 14 (TNSres) -- The American Society of Hematology issued the following news release:
* * *
LBA-6: Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
* * *
The targeted drug zanubrutinib showed superior efficacy with . . .
* * *
LBA-6: Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
* * *
The targeted drug zanubrutinib showed superior efficacy with . . .